FDA Approval Activities for this Drug
REYATAZ (atazanavir) capsules, 100mg, 150mg and 200mg Bristol-Myers Squibb NDA 21-567 REYATAZ (atazanavir) Capsules, Bristol-Myers Squibb REYATAZ (atazanavir) tablets, Bristol-Myers Squibb, New Dosage Regimen | REYATAZ (atazanavir) capsules, Bristol- Myers Squibb, Labeling Revision | Reyataz (atazanavir sulfate) Capsules, Bristol-Myers, Labeling Revision | Reyataz (atazanavir sulfate) Capsules, Bristol-Myers Squibb, Labeling Revision | Reyataz (atazanavir sulfate) Capsules, Bristol-Myers Squibb, Formulation Revision | Reyataz (atazanavir) capsules, Bristol-Myers Squibb, Labeling Revision | Reyataz (atazanavir) Capsules, Bristol-Myers Squibb, Labeling Revision | Atazanavir Sulfate Capsules, Emcure Pharma, Tentative Approval | Reyataz (atazanavir sulfate) Capsules, Bristol-Myers Squibb, Labeling Revision | REYATAZ (atazanavir sulfate) Capsules, Bristol-Myers Squibb, Patient Population Altered | REYETAZ (atazanavir sulfate) Capsules, Bristol-Myers Squibb Co., Labeling Revision | Reyataz (atazanavir sulfate) Capsules, Bristol-Myers Squibb Co., Patient Population Altered | Reyataz (atazanavir sulfate) Capsules, Bristol Myers Squibb, Efficacy Supplement with Clinical Data to Support | REYATAZ (atazanavir sulfate) Capsules, Bristol-Myers Squibb Co., Efficacy Supp. w/Clinical Data | Reyataz (atazanavir sulfate) Capsules, Bristol-Myers Squibb Co., Labeling Revision